This inventor holds 1 USPTO granted patent. Top assignees: Amylin Pharmaceuticals, Inc., Astrazeneca Pharmaceuticals LP. Active years: 2013.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 164 
1 out of 40 
Years Active: 2013
Title: Matthew Wintle: Innovator in Metabolic Disease Treatment
Introduction
Matthew Wintle is a notable inventor based in San Diego, CA. He has made significant contributions to the field of metabolic disease treatment, particularly through his innovative patent.
Latest Patents
Wintle holds a patent for the use of Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease. The present invention relates generally to the novel use of incretin compounds (ICs) and amylinomimetic compounds to treat, prevent, or ameliorate a variety of metabolic conditions or diseases. This patent highlights his commitment to advancing medical science and improving patient outcomes.
Career Highlights
Throughout his career, Wintle has worked with prominent companies in the pharmaceutical industry. He has been associated with Amylin Pharmaceuticals, Inc. and AstraZeneca Pharmaceuticals LP. His work in these organizations has allowed him to contribute to significant advancements in drug development.
Collaborations
Wintle has collaborated with notable professionals in his field, including Dennis Kim and David G. Maggs. These partnerships have further enriched his research and innovation efforts.
Conclusion
Matthew Wintle's contributions to the treatment of metabolic diseases through his patent and career in the pharmaceutical industry underscore his role as an influential inventor. His work continues to impact the field positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile